水疗改善了纤维肌痛患者自我报告的睡眠质量:系统性审查和元分析
Cristina Bravo1,2,3,4, Francesc Rubí-Carnacea1,2,3, Iolanda Colomo1
1Department of Nursing and Physiotherapy, University of Lleida, Montserrat Roig St. n2 P.C, 25198, Lleida, Spain.
Sleep & breathing = Schlaf & Atmung
|October 17, 2023
概括
水疗有望改善纤维肌痛患者的疼痛和睡眠质量. 这次审查表明,它可以作为一种补充治疗来提高生活质量.
科学领域:
- 类风湿病学 类风湿病学
- 物理疗法物理治疗
- 基于证据的医学基于证据的医学.
背景情况:
- 纤维肌痛是一种慢性疾病,具有广泛的疼痛,疲劳和睡眠障碍的特征.
- 目前用于纤维肌痛的治疗方法往往提供有限的缓解,需要探索替代疗法.
- 水疗,利用水的特性进行治疗运动,是一种潜在的非药物干预.
研究的目的:
- 系统地审查和元分析水疗治疗纤维肌痛的有效性.
- 评估水疗对疼痛,睡眠质量,心理症状,生活质量和健康状况的影响.
- 综合了关于纤维肌痛水疗的随机对照试验 (RCT) 的证据.
主要方法:
- 在主要数据库 (PubMed,CINAHL,Cochrane Library,PEDro,Scopus) 进行了全面的文献搜索,截至2022年10月.
- 包括涉及成年纤维肌痛患者和水疗的随机对照试验 (RCT).
- 使用Cochrane风险偏见工具评估方法质量,使用GRADE方法对证据质量进行分级.
主要成果:
- 22个RCT从最初确定的375篇文章中满足了纳入标准.
- 观察到有利于水疗改善睡眠质量的趋势 (匹兹堡睡眠质量指数),尽管在统计学上不显著 (WMD = -1.71,p = 0.17).
- 在短期内,人们注意到疼痛明显改善,有利于水疗 (纤维肌痛影响问卷;WMD = -5.04,p = 0.02),具有相当大的异质性.
结论:
- 水疗是一种有效的辅助治疗,用于控制纤维肌痛症状.
- 水中治疗炼对成年纤维肌痛患者的睡眠质量,疼痛减轻和改善生活质量有好处.
- 建议进行进一步的研究,以调查水疗在纤维肌痛管理中的长期影响.
相关概念视频
Substance Use Disorders Affecting Sleep
174
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
174
Sedatives and Hypnotics Drugs: Miscellaneous Agents
183
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
183
Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Management of Insomnia
260
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
260
Insomnia
88
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
88


